An expanded role from further combination of business areas with seventeen direct report project leaders based in Sweden, UK and USA with technology base expanded to cover super-high resolution microscopy platforms, bio-molecular interaction systems and the Biacore surface plasmon resonance label free protein analysis systems.• delivered move to Agile based Portfolio and Project management• leveraged GE software centre of excellence to deliver multimillion dollar software programme• embedded Fastworks methodologies to embed customer learning and engagement to enable a 'fail fast' culture across the whole portfolio• delivery of new Biacore platform the largest single NPI in the Lifescience business

An expanded role resulting from the combination of three P&L teams to create the larger BioResearch Tools P&L supporting a broader technology base with teams located in Sweden as well as the UK and Germany. Direct reports increased to eleven with two based in Sweden.• Technology breadth expanded to cover stem cell technology and lab media products in addition to consumables portfolio• Portfolio budget almost doubled and revenue supported >$0.5Bn• Project portfolio ranged from delivery of a novel cardiomyocyte stem cell product aimed at drug toxicity testing through size exclusion media for protein separation to laboratory consumables• Piloted Fastworks ways of working to secure customer input and engagement early in the development process• local lead for restructuring activity which led to overall headcount reduction and efficiency savings in the group

Led a group of seven Project Managers and one Portfolio Leader supporting ~60 R&D staff in the Consumables P&L which covered a broad portfolio of products from molecular biology kits and tools through diagnostic membranes to laboratory consumables providing products to scientists in research, development and analysis across many industries. The group had a multi-million dollar annual budget supporting >$0.3Bn sales revenue• responsibility for delivering New Product Introductions, Research and Product Care projects to time, quality and budget• delivered annual planning for the group collating and ranking proposals, budgeting and presenting the plan to senior leadership• execution of the roadmap to plan• improved delivery and decision making in projects, resulting in 11 NPIs being launched in one year• use of design for six sigma and lean principles in early project phases mandated• embedded design for manufacturability, design for usability expectations in projects• chairing monthly Project Committees, the key stakeholder review of projects in the group• presenting performance and delivery to global teams and leadership• global project execution from China through Europe to USA• ensuring professional development and skills development of the Project Leaders

Reporting to the R&D Portfolio Leader and supporting a team of nine project managers delivering global R&D portfolio I was responsible for:• securing continuous improvement and effective project delivery,• supporting annual planning and budgeting cycles,• collecting and reporting performance and forecast data to the P&L leadership, • interfacing with QA, EHS and other functions to establish better ways of working• took on the project management of refitting the local laboratories, securing business funding to upgrade the capability and add new industry standard workflows such as those use in forensics. Supporting a portfolio team of nine, I had one direct report.

A division of GE Healthcare with ~10k employees serving multiple global markets with a broad range of technologies and solutions.Delivered a diverse portfolio of strategic projects:• improved process and workflow for delivering samples to customers, • seconded to deliver OEM NPI for R&D group,• produced a business relocation analysis and strategy

Short term contract providing Quality Systems development project support to support improvement and future sustainability.

Promoted to the management team to develop systems to allow project review board to manage control and priority of critical programmes whilst managing critical projects – 6 direct reports.• Led multi-faceted project to deliver a seasonal influenza assay at point of care. A European Union funded project (€3M) featuring seven partners across Europe and Asia.• Organised and delivered a successful technology readiness evaluation programme with the US Department of Defence involving development and testing a new multiplexed assay in 3 months.• Delivered CE marked instrument platform for veterinary and biothreat applications.• Established credible plan and budget to deliver a novel influenza assay development for a global pharmaceutical partner against a challenging timeline.

A fast growing private sector-public partnership spun out from Dstl at Porton Down developing in-vitro diagnostic and defence based DNA test platforms and assays. Initially a group of 22 people the company opened the San Diego technical centre in November 2009. Recruited to install professional working practices to deliver successful projects in a team centred collaborative environment between internal resources and external partners.• Led instrument validation programme which established documented and controlled instrument performance characteristics.• Delivered ISO9001 certification to plan and implemented ISO13485 compliant system to support medical device development projects.• Re-specified the instrument and consumable systems; established appropriate development controls resulting in a successful 18 month engineering programme.

Based at a partner franchise that manufactured on behalf of ASP through sub-contract. A complex situation requiring tact, diplomacy and persuasion skills to effect maximum benefit for both groups.This was a UK based ‘outpost’ role reporting to the parent franchise in Irvine, California to manage a line extension project for an existing product range, which required extensive global coordination, while maintaining supply chain – 2 direct reports.• Effected aggressive project to evaluate biocide interaction with disinfection apparatus.• Accomplished reestablishment of credible stability trial programme for biocide products.• Ad-hoc troubleshooting of manufacturing processes including use of six sigma based process.• Defined test programme for product compliance to new regulations with French test facility.

Seconded from this global provider of technical services to BMS, initially to perform a gap analysis of a product in development and then providing audit and quality systems support as the project evolved.• Gap analysis of Device Master Record and supporting documentation for Class III medical device.• Audit of potential manufacturing and product support facilities (Europe, USA and Asia).• Definition and training of Design Control approach for newly formed device team at BMS.• Travelled globally representing both BMS and Washington to service providers and partners.

Interim position investigating medical device feasibility for novel technology.

A commercial spin-out from UMIST, employing 60 people at its peak. The company acquired a division of Roche in Georgia USA and relocated with the core critical team there in 2003.• Transformation of multi technique diagnostic project to putative molecular diagnostics platform project. • Trialled concepts with clinical partners to establish technology viability• Initiator, compiler and controller of Design Control dossiers and provider of regulatory input to project initiation phases. • Supporting project from technology evaluation to technology transfer at new site. • Provider of budget and market forecasts, market surveys, data gathering and initial project and resource planning. • Instigated significant change and improvement projects for critical GMP elements within Osmetechs core technology. • Direct report to CEO and CFO based in the UK.

A commercial spin-out from UMIST, employing 60 people at its peak. The company acquired a division of Roche in Georgia USA and relocated with the core critical team there in 2003.Initially employed in the application group the role expanded as the company transformed into an in-vitro medical device developer. Reporting directly to the CEO. Three direct reports.• Project leader for development of point of care platform, initially specified for women’s healthcare, integrating novel sensor technology with established immuno-assay approaches. Delivered to proof of concept stage in a multipartner project with a budget of ~£6M.• Key team member in shut down of UK operation and relocation to USA.• Successful 510k submissions for Bacterial Vaginosis and Urinary Tract Infection products.

A commercial spin-out from UMIST, employing 60 people at its peak. • Development and validation of headspace analysis techniques for UTI and later Bacterial Vaginosis detection projects.